← Syndax Pharmaceuticals, Inc. (SNDX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Syndax Pharmaceuticals, Inc. (SNDX)
Pharmaceutical Preparations · market cap $1.6B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-02 (est.)
Earnings
Pipeline
7
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Syndax Pharmaceuticals (SNDX) is a ~$2.1B market cap clinical-stage pharma with 270 employees, best known for its menin inhibitor revumenib, now in Phase 3 for colorectal cancer. The company carries ~$213M net debt, only ~7.8 months of cash runway, and posted a $285M net loss in 2025 against $172M in revenue, implying heavy near-term financing risk.
The catalyst path
- 2026-11-02 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| cobicistat | Phase 2 | Acute Myeloid Leukemia |
| entinostat | Phase 2 | Non-Small Cell Lung Cancer |
| Aromatase Inhibitor (AI) Therapy | Phase 2 | ER+ Breast Cancer |
| Revumenib | Phase 3 | Colorectal Cancer |
| Intensive Chemotherapy Regimen | Phase 3 | Acute Myeloid Leukemias |
| avelumab | Phase 2 | Epithelial Ovarian Cancer |
| Axatilimab | Phase 2 | Chronic Graft-versus-host-disease |
Price & technical context
3-month
-10.0%
6-month
-19.5%
12-month
+22.2%
52-wk range
$13.11–$25.15
vs 50-day MA
-3.2%
vs 200-day MA
-10.1%
Realized vol
72.2%
Max drawdown
-60.0%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SNDX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.